BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28785596)

  • 1. Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.
    Van den Bergh JMJ; Smits ELJM; Versteven M; De Reu H; Berneman ZN; Van Tendeloo VFI; Lion E
    J Immunol Res; 2017; 2017():1975902. PubMed ID: 28785596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
    Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
    Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
    Michiels A; Tuyaerts S; Bonehill A; Corthals J; Breckpot K; Heirman C; Van Meirvenne S; Dullaers M; Allard S; Brasseur F; van der Bruggen P; Thielemans K
    Gene Ther; 2005 May; 12(9):772-82. PubMed ID: 15750615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation.
    Stonier SW; Ma LJ; Castillo EF; Schluns KS
    Blood; 2008 Dec; 112(12):4546-54. PubMed ID: 18812469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
    Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
    Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
    Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
    Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.
    Van den Bergh JM; Lion E; Van Tendeloo VF; Smits EL
    Pharmacol Ther; 2017 Feb; 170():73-79. PubMed ID: 27777088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
    Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
    Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-independent immune responses after dendritic cell vaccination.
    Leonhartsberger N; Ramoner R; Putz T; Gander H; Rahm A; Falkensammer C; Bartsch G; Thurnher M
    Cancer Immunol Immunother; 2007 Jun; 56(6):897-903. PubMed ID: 17106716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
    Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
    Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.
    Van Meirvenne S; Dullaers M; Heirman C; Straetman L; Michiels A; Thielemans K
    Mol Ther; 2005 Nov; 12(5):922-32. PubMed ID: 16257383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.
    Erdmann M; Dörrie J; Schaft N; Strasser E; Hendelmeier M; Kämpgen E; Schuler G; Schuler-Thurner B
    J Immunother; 2007 Sep; 30(6):663-74. PubMed ID: 17667530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.